HemaCare and Tissue Solutions Announce Strategic Partnership to Expand Access to Human Disease-State Samples

Advancing discoveries by providing scientists with high-quality
disease-state biospecimens to support preclinical and clinical research

LOS ANGELES & GLASGOW, Scotland–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/apheresis?src=hash" target="_blank"gt;#apheresislt;/agt;–HemaCare
Corporation (OTCMKTS: HEMA), a global leader and trusted brand in
the customization of human-derived biological products and services for
biomedical research, drug discovery, and cellular therapy process
development, and Tissue
Solutions Ltd, a leading global provider of diseased human
biosamples for research, today announced their partnership to supply
customers with an expanded selection of well-qualified disease-state
biomaterials in fresh, frozen, and FFPE formats.

Access to patient-donor material is an immense challenge researchers and
pharmaceutical companies face when sourcing human starting material. As
a therapy or drug moves through research and development to
commercialization, the need for donor samples that meet specific disease
criteria increases as it offers the closest approximation of real-life
cellular responses.

Partnering with Tissue Solutions will allow HemaCare to further meet
growing market needs by expanding its current disease-state product
portfolio. HemaCare customers will now have access to pathology-verified
frozen and FFPE tissues, as well as hard-to-source disease samples such
as tumor tissues and dissociated tumor cells isolated from freshly
resected tumors.

“HemaCare has seen a high demand from scientists and clinical
researchers for blood and other tissue samples from diseased patients,”
said Lou Juliano, HemaCare’s SVP of Global Sales and Business
Development. “Tissue Solutions is already one of HemaCare’s preferred
European distributors and this expanded partnership allows our customers
to readily access over 110 million banked human samples sourced through
a network of more than 500 qualified suppliers.”

Commitment to supporting scientists is a chief priority for HemaCare and
Tissue Solutions. By partnering to expand the disease-state product
offerings, researchers will be able to access well-characterized
disease-state starting material within a short turnaround time. With
faster access to such material, a researcher can accelerate their
research timelines and focus on curing human disease.

“We are delighted to expand our partnership with HemaCare as their
commitment to quality has always been the best in the industry,”
said Morag McFarlane, Ph.D., Tissue Solutions’ Chief Executive Officer. “HemaCare
is our preferred apheresis provider and we utilize their extensive donor
database for a majority of customer requests. The expanded partnership
will help provide HemaCare’s customers with a broadened portfolio of
well-qualified disease tissues and normal adjacent tissue or matched
tumor tissue from the same donor where necessary.”

HemaCare’s expanded biospecimen portfolio can be found here.
For general information about products visit HemaCare’s website at www.hemacare.com.

For more information about Tissue Solutions please visit www.tissue-solutions.com.

About HemaCare

HemaCare is a global leader in the customization of human-derived
biological products and services for biomedical research, drug discovery
and cellular therapy process development. The company’s network of
FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor
material is available to customers and for use within HemaCare’s
isolation laboratory. Human biological material including peripheral
blood, bone marrow, and cord blood is isolated into various primary
cells types for fresh and frozen distribution. For over 40 years,
HemaCare has developed an extensive registry of repeat donors
and provides human-derived primary blood cells and tissues for
biomedical and drug discovery research and cell therapy clinical trials,
and supports commercialization with apheresis collections, directly
enabling customers to advance both autologous and allogeneic cellular
therapies.

About Tissue Solutions

Tissue Solutions is a customer-focused global provider of ethically
sourced human samples required for preclinical drug development and
research. The ISO 9001 (2015) accredited company provides a tissue
provision service through a global network to individual requirements
ensuring projects are not constrained by access to human biomaterials or
collection timelines. Tissue Solutions also offers a comprehensive
integrated range of tissue related GLP/GCP compliant IHC and Histology
services, offering a single access point for pre-clinical and clinical
research. Services include sourcing difficult to obtain samples for a
range of applications such as target identification and validation,
biomarker studies, companion diagnostics, pharmacogenetics and safety
testing. They specialize in sourcing “tough” tissues, e.g. fresh
samples, skin biopsies. The management team has a wealth of experience
gained from many years in the biotech and pharmaceutical industry with
expertise on ethics and compliance, and logistics.

Contacts

HemaCare
Maria Thompson
[email protected]
619-722-0970

Tissue Solutions
Fiona Mackenzie
[email protected]
0141
299 0055